Terbutaline and other beta - agonist drugs do not cause autism spectrum disorders

Introduction To describe the relationship or lack thereof, between Betaagonist drugs such as terbutaline and autism. Relevant scientific publications regarding autism spectrum disorders were reviewed. The data in both human and animal studies regarding Beta-agonist drugs used for treatment of asthma as well as preterm labour were interrogated for potential association with Autism Spectrum Disorders. The likelihood of causality was tested using the appropriate epidemiologic criteria. Discussion The prevalence of Autism Spectrum Disorders has increased substantially over past decades. Genetics plays a predominant role in causation, being involved in nearly 90% of known cases. In a minority of patients there is a causal relationship between drugs such as thalidomide or valproic acid, and Autism Spectrum Disorder. The vast preponderance of the literature confirms that the use of beta-agonist drugs, particularly during pregnancy as treatment for preterm labour and asthma are not related in any scientific way to autism spectrum disorders. Conclusion It can now be stated conclusively that exposure to betaagonist drugs during pregnancy does not increase the risk of Autism Spectrum Disorder. Terbutaline and other betaagonist drugs should be used during the prenatal period based on the physician’s perceived need for the medication because asthma and prematurity issues are of the utmost importance.